Clicky

Hepion Pharmaceuticals, Inc.(HEPA)

Description: Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.


Keywords: Medicine Biopharmaceutical Phosphates Hepatitis B Liver Disease Lipid Hepatotoxins Gilead Sciences Edison Drug Therapy Treatment Of Hepatitis Treatment Of Hepatitis B Chronic Liver Disease Cyclophilin Purines Chronic Liver Diseases Tenofovir Disoproxil Phosphonate

Home Page: www.hepionpharma.com

HEPA Technical Analysis

399 Thornall Street
Edison, NJ 08837
United States
Phone: 732 902 4000


Officers

Name Title
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. Pres, CEO & Director
Mr. John T. Cavan Chief Financial Officer
Dr. Todd M. Hobbs M.D. Chief Medical Officer
Dr. Launa J. Aspeslet Ph.D. Chief Operating Officer
Dr. Daren Ure Ph.D. Chief Scientific Officer
Sharen Pyatetskaya Director of Investor Relations
Dr. Daniel J. Trepanier Ph.D. Sr. VP of Drug Devel.
Dr. Patrick R. Mayo Ph.D. Sr. VP of Clinical Pharmacology
Dr. John Z. Sullivan-Bolyai Part-Time Consultant
Dr. Stephen A. Harrison M.D. Member of Scientific Advisory Board & Consultant Medical Director

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4172
Price-to-Sales TTM: 0
IPO Date: 2014-02-11
Fiscal Year End: December
Full Time Employees: 20
Back to stocks